NCT00706992 2015-10-28Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma PatientsNational Institutes of Health Clinical Center (CC)Phase 2 Terminated50 enrolled 13 charts
NCT00005949 2013-01-16Vaccine Plus Interleukin-2 in Treating Patients With Advanced MelanomaNational Cancer Institute (NCI)Phase 2 Completed50 enrolled